Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.

This content is available also in other languages

x

This content is available also in other languages

June 24, 2015 | Customer News

Automated PBMC isolation for biobanking with Tecan’s Freedom EVO®

June 24, 2015

Automated PBMC isolation for biobanking with Tecan’s Freedom EVO®

PBMCs are extracted from centrifuged whole blood using a novel automated protocol on a Freedom EVO workstation

Männedorf, Switzerland, June 24, 2015 – IBBL (Integrated BioBank of Luxembourg) has developed the world’s first fully automated technique for the isolation of viable peripheral blood mononuclear cells (PBMCs) using a Freedom EVO® workstation. Dr Fay Betsou, Chief of Biospecimen Science, explained: “PBMCs are of increasing interest for vaccine development and validation, and we have seen a steady increase in requests for PBMC-based functional assays. These cells – primarily lymphocytes and monocytes – are traditionally extracted manually using a laborious and time-consuming Ficoll-Paque method, taking a technician approximately four hours to isolate PBMCs from 10 samples.”

Taking advantage of the advanced liquid handling capabilities of the Freedom EVO platform, IBBL has developed a straightforward automated protocol based on the use of standardized citrate anticoagulant tubes (BD Vacutainer® CPT™). This walkaway process allows efficient isolation of PBMCs for cryopreservation while minimizing the number of granulocytes present in the final preparation. Fay continued: “This validated1 protocol is based on the mean hematocrit of the general population, and offers recovery rates and viability comparable to the manual process. This protocol can now be implemented as part of our standard portfolio of automated methods and, although high throughput is not our primary focus, the Freedom EVO system offers walkaway processing of 24 patient samples in under three hours, allowing the technician to perform other activities while it is running.”

1Hamot et al. Method Validation for Automated Isolation of Viable Peripheral Blood Mononuclear Cells. Biopres Biobank, 2015, In press.

To find out more on Tecan’s biobanking solutions, visit www.tecan.com/biobanking

 
For more information please contact

Tecan Trading AG
Antonietta Allocca
Seestrasse 103
CH-8708 Männedorf

Tel +41 (0)44 922 81 11
Fax +41 (0)44 922 81 12

info@tecan.com
www.tecan.com



About Tecan

Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2014, Tecan generated sales of CHF 400 million (USD 437 million; EUR 331 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).

About IBBL

The IBBL (Integrated BioBank of Luxembourg) Institute is a biobank dedicated to supporting biomedical research for the benefit of patients. The mission of IBBL is to provide high-quality biospecimens and associated data, foster scientific excellence, catalyse partnerships and support research that translates scientific discoveries into new healthcare solutions. IBBL is an integrated research infrastructure, compliant with international quality standards, offering biobanking services, including the collection, processing, analysis and storage of biological samples and associated data. In addition, IBBL carries out research to optimise biospecimen processing and certify biospecimen quality. IBBL is an autonomous institute, organised within the Luxembourg Institute of Health (LIH). For more information, please visit our corporate website (www.ibbl.lu) or our public website (www.biobank.lu)